Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 1/20 | 0.50 |
| ▸ | F3 | P13726 | 1/20 | 0.50 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.50 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.50 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.50 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.50 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.50 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.50 |
| ▸ | SIRT4 | Q9Y6E7 | 1/20 | 0.50 |
| ▸ | CDK1 | P06493 | 1/20 | 0.41 |
| ▸ | CDK4 | P11802 | 1/20 | 0.41 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.41 |
| ▸ | CCND1 | P24385 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | SLC5A1 | P13866 | 2/20 | 0.40 |
| ▸ | SLC5A2 | P31639 | 2/20 | 0.40 |
| ▸ | SLC28A3 | Q9HAS3 | 2/20 | 0.39 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.39 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.39 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Niacinamide SCHEMBL28136690 | 0.92 | F7 (0.51) | F7F3SARM1SIRT2SIRT6 | |
| Niacinamide SCHEMBL20398298 | 0.91 | F7 (0.55) | F7F3SARM1SIRT2SIRT6 | |
| Niacinamide SCHEMBL28825303 | 0.87 | F7 (0.44) | F7F3SARM1SIRT2SIRT6 | |
| Niacinamide SCHEMBL28825343 | 0.87 | F7 (0.44) | F7F3SARM1SIRT2SIRT6 | |
| Niacinamide SCHEMBL21571784 | 0.86 | F7 (0.50) | F7F3SARM1SIRT2SIRT6 | |
| Niacinamide SCHEMBL28137384 | 0.86 | F7 (0.50) | F7F3SARM1SIRT2SIRT6 | |
| Niacinamide SCHEMBL502654 | 0.85 | F7 (0.49) | F7F3SARM1SIRT2SIRT6 | |
| SCHEMBL25387949 | 0.84 | ALDH1A1 (0.46) | MAOBSLC28A3LGALS9LGALS1LGALS3 | |
| SCHEMBL21828727 | 0.84 | ALDH1A1 (0.46) | MAOBSLC28A3LGALS9LGALS1LGALS3 | |
| SCHEMBL29993128 | 0.84 | ALDH1A1 (0.46) | MAOBSLC28A3LGALS9LGALS1LGALS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10316054-B2 | Preparation and use of crystalline beta-D-nicotinamide riboside | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2019-06-11 | — | — | US | disclosed |
| US-20170204131-A1 | PREPARATION AND USE OF CRYSTALLINE BETA-D-NICOTINAMIDE RIBOSIDE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-07-20 | — | — | US | disclosed |
| EP-3149016-A1 | PREPARATION AND USE OF CRYSTALLINE BETA-D-NICOTINAMIDE RIBOSIDE | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2017-04-05 | — | — | EP | disclosed |
| WO-2015186068-A1 | PREPARATION AND USE OF CRYSTALLINE BETA-D-NICOTINAMIDE RIBOSIDE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2015-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170204131-A1 | PREPARATION AND USE OF CRYSTALLINE BETA-D-NICOTINAMIDE RIBOSIDE | NNT, HADHB, NAMPT | F7 3551/4885F3 2206/4885SARM1 105/4885 |
| US-10316054-B2 | Preparation and use of crystalline beta-D-nicotinamide riboside | NNT, HADHB, NAMPT | F7 3551/4885F3 2206/4885SARM1 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.